Pharmaceutical care of serious adverse reactions due to methotrexate treatment of ectopic pregnancy

doi:10.19803/j.1672-8629.20230616

Abstract

Abstract: Objective To monitor the use of methotrexate for the treatment of one ectopic pregnancy patient based on the China Hospital Pharmacovigilance System (CHPS) so as to explore the role of clinical pharmacists in providing pharmacological care. Methods The process in which clinical pharmacists monitored adverse reactions during methotrexate therapy in a patient with ectopic pregnancy through the CHPS and participated in revising the medication regimen was analyzed. Results and Conclusion Clinical pharmacists can monitor adverse drug reactions via the CHPS, assist clinicians in treating adverse reactions, ensure the safety of medication, and improve the quality of pharmacy services.

Key words: ectopic-pregnancy, methotrexate, adverse drug reactions, clinical pharmacist, Chinese Hospital Pharmacovigilance System, pharmaceutical care

CLC Number:

R984
R994.11

LI haiyan, YANG Zhongxu, LIU Yuekun, WANG Lihong. Pharmaceutical care of serious adverse reactions due to methotrexate treatment of ectopic pregnancy[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 454-456.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20230616

https://www.zgywjj.com/EN/Y2024/V21/I4/454

References

[1] SONG Z, HU Y, LIU S, et al.Medication therapy of high-dose methotrexate: an evidence-based practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society[J]. Br J Clin Pharmacol, 2022, 88(5): 2456-2472.
[2] ZHANG CY, REN XL, FENG WY, et al.The effect of MTHFR and ABCB1 genetic polymorphism on serious toxicity and elimination delay of high dose methotrexate[J]. Chinese Journal of New Drugs(中国新药杂志), 2019, 28(1): 117-120.
[3] BAI XH, NIU HJ, NI MY, et al.Association of MTHFR gene polymorphism with efficacy and adverse drug reactions of high-dose methotrexate in the treatment of childhood acute lymphoblastic leukemia[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2021, 37(22): 3056-3059.
[4] LIU S, SONG ZW, YI ZM, et al.Hematotoxicity correlation of MTHFR gene polymorphism with high-dose of methotrexate in hematological neoplasm patients:a Meta-analysis[J]. China Pharmacy(中国药房), 2020, 31(7): 850-858.
[5] SONG ZW, HUANG ZC, ZHAO RS.Pharmacogenetics of methotrexate toxicity in patients with osteosarcoma or hematological malignancy: an umbrella review of systematic reviews[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2019, 35(9): 896-899.
[6] DENG GP, GAO J, ZHANG YX, et al.Tubal pregnancy diagnosis and treatment guide of integrated Chinese and western medicine[J]. Chinese Journal of Practical Gynecology and Obstetrics(中国实用妇科与产科杂志), 2021, 37(2): 172-180.
[7] PO L, THOMAS J, MILLS K, et al. Guideline No.414: management of pregnancy of unknown location and tubal and nontubal ectopic pregnancies[J]. J Obstet Gynaecol Can, 2021, 43(5): 614-630. e1.
[8] ALUR-GUPTA S, COONEY LG, SENAPATI S, et al. Two-dose versus single-dose methotrexate for treatment of ectopic pregnancy: a meta-analysis[J]. American Journal of Obstetrics and Gynecology, 2019, 221(2): 95-108. e2.
[9] BARNHART KT, GOSMAN G, ASHBY R, et al.The medical management of ectopic pregnancy: a meta-analysis comparing ‘single dose'and‘multidose'regimens[J]. Obstetrics and Gynecology, 2003, 101(4): 778-784.
[10] YOU LN, XU H, XIA HY, et al.Retrospective analysis on methotrexate in the treatment of ectopic pregnancy[J]. Medical and Pharmacy of Yunnan(云南医药), 2022, 43(1): 24-27.
[11] XIE H, KONG BH, DUAN T.Obstetrics and Gynecology(妇产科学)[M]. 9th Edition. Beijing: People's Health Press, 2018: 74-79.
[12] GUO C, HUANG G, LIN F, et al.Expert consensus on high-dose methotrexate calcium folinate rescue therapy for malignant tumors[J]. Chinese Clinical Oncology(中国肿瘤临床), 2019, 46(15): 761-767.
[13] QIN SK, MA J.Chinese Society of Clinical Oncology (CSCO) guidelines for standardized management of tumor chemoradiotherapy-related neutropenia ( version 2021)[J]. Chinese Clinical Oncology(临床肿瘤学杂志), 2021, 26(7): 638-648.
[14] SUN ZM, HUANG XJ, WANG Y, et al.Guidelines for clinical application of antimicrobial drugs in Chinese patients with neutrophil deficiency with fever (2020 version)[J]. Chinese Journal of Hematology(中华血液学杂志), 2020, 41(12): 969-978.

[1]	YANG Bo, WANG Mengjiao, HU Lili, WANG Laicheng, LI Qian, KONG Feifei, LYU Dongmei, SHEN Jiani. Safety assessment and risk factor analysis of PD-1 immunotherapy in a cohort of 385 patients [J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 447-450.
[2]	LI Shaoqiang, KONG Xudong, LI Pengmei. One case of hyponatremia caused by omeprazole sodium for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 461-463.
[3]	WU Shiqi, YAN Suying, ZHANG Qingxia. Research progress in pharmacokinetic interactions of edoxaban [J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 473-480.
[4]	LIU Qi, ZHANG Yufeng, LUO Hao, LI Xin. Analysis of the rationality and safety of clinical application of anrotinib in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 329-334.
[5]	JI Qiuxia, JIN Jian, ZHANG Bin. Pharmaceutical care for immune-related adverse events induced by toripalimab [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 346-348.
[6]	YANG Xueting, HE Bo, YAN Hongli, LI Dongmei. One case of acute transient depression caused by clarithromycin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 352-354.
[7]	FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
[8]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[9]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[10]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[11]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[12]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[13]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[14]	ZANG Tianying, LIU Bingyang, TANG Xiaojun. Differentiation of vancomycin induced anaphylactoid and anaphylactic reactions [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1078-1080.
[15]	ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan. Medications of apatinib mesylate in patients with malignant tumors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.